12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Budget, Economic Development, Government Procurement, Health	Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions	Legislative Proposal, Bill or Resolution, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Engagement with the Government regarding the Strategic Innovation Fund	Grant, Contribution or Other Financial Benefit, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario	Grant, Contribution or Other Financial Benefit, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients.	Policies or Program

  Subject matters in previous versions

  • Budget
  • Economic Development
  • Government Procurement
  • Health
  • Intellectual Property
  • Research and Development

  Subject matters added through a communication report:

  • Budget
  • Economic Development
  • Government Procurement
  • Health
  • Immigration
  • Research and Development

Government Institutions

• Canadian Heritage (PCH)
• Correctional Service of Canada (CSC)
• Employment and Social Development Canada (ESDC)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Immigration, Refugees and Citizenship Canada (IRCC)
• Indigenous Services Canada (ISC)
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Pacific Economic Development Canada (PacifiCan)
• Patented Medicine Prices Review Board (PMPRB)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Public Services and Procurement Canada (PSPC)
• Senate of Canada
• Treasury Board Of Canada Secretariat (TBS)
• Veterans Affairs Canada (VAC)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Oral communication
• Written communication
• Arrange one or more meetings

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Josee Gravelle, General Counsel | No public offices held
• Kristen Kazlovskis, Business Unit Head, Specialty and Oncology | No public offices held
• Gilda Volpentesta, VP of Regulatory | No public offices held
• Emma Walmsley, Global Chief Executive Officer | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Emily Beduz, Manager, Federal Affairs | No public offices held
• Stephen Burke, National Policy Manager - Oncology | No public offices held
• Daniel Clow, Director, Ethics and Compliance | No public offices held
• Alain Couture, External Affairs Manager | No public offices held
• Elle Doherty, External Engagement Manager, Infectious Disease and Future Pipeline Policy | No public offices held
• Ryan Lock, Manager, National Policy - Federal Affairs | No public offices held
• Alison Pozzobon, Interim Head, Government Affairs & Market Access | No public offices held
• Kevin Sauve, National Public Health Manager | No public offices held
• Shawn White, External Affairs Manager | No public offices held

• Lobbyists in previous versions

  Senior Officers whose lobbying activities represent less than 20% of their Duties

  • Ranya El-Masri, VP Public Affairs and Reimbursement | No public offices held